Michael Loken
Overview
Explore the profile of Michael Loken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stevens A, Terrell M, Rashid R, Fisher K, Marcogliese A, Gaikwad A, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397996
The survival rate of pediatric acute myeloid leukemia (pAML) is currently around 60%. While survival has slowly increased over the past few decades, the development of novel agents likely to...
2.
Pommert L, Cooper T, Gerbing R, Brodersen L, Loken M, Gamis A, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158884
International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia (AML) for regulatory purposes. However, these...
3.
Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith J, et al.
PLoS One
. 2021 Nov;
16(11):e0259197.
PMID: 34793513
Infant Acute Myeloid Leukemia (AML) is a poorly-addressed, heterogeneous malignancy distinguished by surprisingly few mutations per patient but accompanied by myriad age-specific translocations. These characteristics make treatment of infant AML...
4.
Elgarten C, Wood A, Li Y, Alonzo T, Brodersen L, Gerbing R, et al.
Pediatr Blood Cancer
. 2021 Oct;
68(12):e29281.
PMID: 34596937
Background: High-risk pediatric acute myeloid leukemia confers a poor prognosis, and alternative strategies are needed to improve outcomes. We hypothesized that intensifying induction on the AAML1031 clinical trial would improve...
5.
Getz K, Alonzo T, Sung L, Meshinchi S, Gerbing R, Raimondi S, et al.
Pediatr Blood Cancer
. 2021 Sep;
69(1):e29313.
PMID: 34472213
Background: The optimal number of chemotherapy courses for low-risk (LR) pediatric acute myeloid leukemia (AML) is not known. Objective: To compare outcomes for four (21.6 g/m cytarabine) versus five (45.6 ...
6.
Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, et al.
Blood
. 2021 Jul;
138(23):2337-2346.
PMID: 34320162
Myeloid leukemia in children with Down syndrome (ML-DS) is associated with young age and somatic GATA1 mutations. Because of high event-free survival (EFS) and hypersensitivity of the leukemic blasts to...
7.
Chauhan L, Shin M, Wang Y, Loken M, Pollard J, Aplenc R, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914031
Purpose: The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for...
8.
Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, et al.
Haematologica
. 2020 Feb;
105(7):1879-1886.
PMID: 32029509
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition...
9.
Valent P, Orazi A, Steensma D, Ebert B, Haase D, Malcovati L, et al.
Oncotarget
. 2017 Nov;
8(43):73483-73500.
PMID: 29088721
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid...
10.
Pollard J, Loken M, Gerbing R, Raimondi S, Hirsch B, Aplenc R, et al.
J Clin Oncol
. 2016 Jan;
34(7):747-55.
PMID: 26786921
Purpose: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet...